Phase 3 Clinical Trials With Primary Completion Dates in December 2018
This is a list of Phase 3 trials with primary completion dates in December 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2018-12-01 | Phase 3 | NCT02970292 | Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) |
| AIMT | Aimmune Therapeutics, Inc. | 2018-12-01 | Phase 3 | NCT03201003 | ARTEMIS Peanut Allergy In Children |
| ALDX | Aldeyra Therapeutics, Inc. | 2018-12-01 | Phase 3 | NCT03494504 | ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis |
| ALDX | Aldeyra Therapeutics, Inc. | 2018-12-01 | Phase 3 | NCT03131154 | SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis. |
| AMPE | Ampio Pharmaceuticals, Inc. | 2018-12-01 | Phase 3 | NCT03349645 | An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee |
| AVEO | AVEO Pharmaceuticals, Inc. | 2018-12-01 | Phase 3 | NCT02627963 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC |
| AXGN | AxoGen, Inc. | 2018-12-01 | Phase 3 | NCT01809002 | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair |
| MD | Mednax, Inc | 2018-12-01 | Phase 3 | NCT02534077 | Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants |
| MMSI | Merit Medical Systems, Inc. | 2018-12-01 | Phase 3 | NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer |
| OCUL | Ocular Therapeutix, Inc. | 2018-12-01 | Phase 3 | NCT02914509 | OTX-16-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-TP in Subjects With Open-Angle Glaucoma and Ocular Hypertension |
| RDHL | Redhill Biopharma Ltd. | 2018-12-01 | Phase 3 | NCT01951326 | Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease |
| SAGE | Sage Therapeutics, Inc. | 2018-12-01 | Phase 3 | NCT02978326 | A Study to Evaluate SAGE-217 in Subjects With Severe Postpartum Depression |
| SLNO | Soleno Therapeutics, Inc. | 2018-12-01 | Phase 3 | NCT03440814 | A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2018-12-01 | Phase 3 | NCT02953340 | Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER) |
| SUPN | Supernus Pharmaceuticals, Inc. | 2018-12-01 | Phase 3 | NCT03247556 | Evaluation of SPN-812 ER High Dose in Adolescents With ADHD |
| URGN | UroGen Pharma Ltd. | 2018-12-01 | Phase 3 | NCT02793128 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study |
| VNDA | Vanda Pharmaceuticals Inc. | 2018-12-01 | Phase 3 | NCT01218789 | Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception |
| ZGNX | Zogenix, Inc. | 2018-12-01 | Phase 3 | NCT02826863 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome |